US Patent No: 7,510,713
Number of patents in Portfolio can not be more than 2000
Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies
Stats
-
Mar 31, 2009
Issued date -
Aug 17, 2007
filing date -
11/840,597
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 6,113,898 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies | 32 | 1995 | |
| 6,709,654 Treatment of psoriasis using anti-B7.1 (CD80) antibodies | 9 | 1999 | |
| 7,175,847 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 | 4 | 2000 | |
| 6,893,638 Methods for treating b cell lymphoma using CD80-specific antibodies | 9 | 2001 | |
| 7,153,508 Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 | 8 | 2002 | |
| 7,192,585 CD80 specific antibodies | 8 | 2005 | |
| 7,425,447 Host cells expressing 7C10 and 16C10 CD80-specific antibodies | 2 | 2006 | |
| 7,417,128 7C10 and 16C10 CD80-specific antibodies | 2 | 2006 | |
|
|
|||
| 5,770,197 Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules | 82 | 1993 | |
| 5,434,131 Chimeric CTLA4 receptor and methods for its use | 131 | 1993 | |
| 5,521,288 CD28IG fusion protein | 84 | 1994 | |
| 5,580,756 B7IG fusion protein | 70 | 1994 | |
| 5,844,095 CTLA4 Ig fusion proteins | 91 | 1995 | |
| 5,885,579 CTLA4 receptor and uses thereof | 36 | 1997 | |
| 6,051,228 Antibodies against human CD40 | 41 | 1998 | |
|
|
|||
| 4,816,567 Recombinant immunoglobin preparations | 1317 | 1983 | |
| 5,116,964 Hybrid immunoglobulins | 435 | 1989 | |
|
|
|||
| 4,816,397 Multichain polypeptides or proteins and processes for their production | 417 | 1984 | |
|
|
|||
| 5,747,034 Methods and materials for the induction of T cell anergy | 35 | 1994 | |
|
|
|||
| 6,162,432 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction | 22 | 1995 | |
|
|
|||
| 5,304,635 Antigen specifically expressed on the surface of B cells and Hodgkin's cells | 15 | 1992 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Sep 30, 2016 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Sep 30, 2020 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |